Comparison of major-bleeding risk and health care costs among treatment-naïve non-valvular atrial fibrillation patients initiating apixaban, dabigatran, rivaroxaban, or warfarinAlpesh Amin, Jeffrey Trocio, K Price et al.|MEF University Institutional Repository (MEF University)|2015Cited by 2
Real-world comparison of major bleeding and associated costs among treatment-naïve nonvalvular atrial fibrillation patients initiating apixaban or warfarinAlpesh Amin, Jeffrey Trocio, Allison Keshishian et al.|MEF University Institutional Repository (MEF University)|2016Cited by 0